Price Disclosure Reductions for 2020 October Cycle

Page last updated: 11 September 2020

This summary only includes medicines taking a price disclosure reduction on 1 October 2020. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should note that:

if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 October 2020 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Outcomes for flow-on price disclosure reductions to F2 combination items were communicated to responsible persons with brands of affected drugs in July 2020.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2020 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 31 March 2020 will also take the reduction on 1 October 2020 under section 99ADHA of the Act.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes was 5pm AEST on 3 July 2020.

Indicative prices for 1 October 2020 (including price to pharmacy, dispensed price for maximum quantity and price premiums) were published on 27 July 2020.

Final prices for 1 October 2020 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from September 2020.

Excel version of 2020 October Cycle Outcomes Summary

2020 October Cycle Outcomes Summary

2020 October Cycle Outcomes Summary
Legal Instrument Drug (drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria)	Legal Instrument MoA	Legal Instrument Form	Average AEMP ($)	WAPD (%) across a drug/MoA	WADP - potential October '20 PBS Price (AEMP) ($) per pharmaceutical item	April '20 AEMP ($)	Percentage difference between April '20 and October '20 PBS prices (AEMP) (%) per pharmaceutical item	Calculations based on: OWAPD = all brand data GWAPD = originator brand data removed for at least one pharmaceutical item No originator brand determined Does not meet 30 month clock	Applicable Unadjusted Price Reduction 10% or 30%
			[Average AEMP minus WAPD = WADP]			[Difference between April '20 AEMP & WADP = % Difference]
acamprosate	Oral	Tablet (enteric coated) containing acamprosate calcium 333 mg	108.07	11.60%	95.53	108.07	11.60%	Does not meet 30 month clock	10
aripiprazole	Oral	Tablet 10 mg	74.47	11.17%	57.33	64.54	11.17%	GWAPD	10
aripiprazole	Oral	Tablet 15 mg	105.68	11.18%	81.35	91.59	11.18%	GWAPD	10
aripiprazole	Oral	Tablet 20 mg	128.64	11.18%	99.03	111.49	11.18%	GWAPD	10
aripiprazole	Oral	Tablet 30 mg	156.76	11.18%	120.67	135.86	11.18%	GWAPD	10
azacitidine	Injection	Powder for injection 100 mg	217.64	13.72%	156.61	181.51	13.72%	GWAPD	10
bosentan	Oral	Tablet 125 mg (as monohydrate)	1113.08	19.30%	898.26	1113.08	19.30%	Does not meet 30 month clock	10
bosentan	Oral	Tablet 62.5 mg (as monohydrate)	1113.08	19.30%	898.26	1113.08	19.30%	Does not meet 30 month clock	10
entecavir	Oral	Tablet 0.5 mg (as monohydrate)	144.49	40.20%	72.51	121.25	40.20%	GWAPD	10
entecavir	Oral	Tablet 1 mg (as monohydrate)	234.98	40.20%	117.91	197.18	40.20%	GWAPD	10
ezetimibe	Oral	Tablet 10 mg	20.86	27.62%	12.71	17.56	27.62%	Does not meet 30 month clock	10
fenofibrate	Oral	Tablet 145 mg	18.39	16.97%	15.27	18.39	16.97%	Does not meet 30 month clock	10
fenofibrate	Oral	Tablet 48 mg	12.26	16.97%	10.18	12.26	16.97%	Does not meet 30 month clock	10
itraconazole	Oral	Capsule 100 mg	109.35	11.09%	97.22	109.35	11.09%	GWAPD	10
itraconazole	Oral	Capsule 50 mg	109.35	11.09%	97.22	109.35	11.09%	GWAPD	10
olmesartan with hydrochlorothiazide	Oral	Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg	5.75	13.28%	4.57	5.27	13.28%	GWAPD	10
olmesartan with hydrochlorothiazide	Oral	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg	10.65	11.60%	8.46	9.57	11.60%	GWAPD	10
olmesartan with hydrochlorothiazide	Oral	Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg	12.04	13.00%	9.57	11.00	13.00%	GWAPD	10
pegfilgrastim	Injection	Injection 6 mg in 0.6 mL single use pre-filled syringe	1175.00	20.43%	934.95	1175.00	20.43%	GWAPD	10
pregabalin	Oral	Capsule 150 mg	24.02	23.31%	18.42	24.02	23.31%	Does not meet 30 month clock	10
pregabalin	Oral	Capsule 25 mg	7.08	23.31%	5.43	7.08	23.31%	Does not meet 30 month clock	10
pregabalin	Oral	Capsule 300 mg	35.84	23.33%	27.48	35.84	23.33%	Does not meet 30 month clock	10
pregabalin	Oral	Capsule 75 mg	15.66	23.31%	12.01	15.66	23.31%	Does not meet 30 month clock	10
rituximab*	Injection	Solution for I.V. infusion 100 mg in 10 mL	479.73	18.94%	388.87	479.73	18.94%	Does not meet 30 month clock	10
rituximab*	Injection	Solution for I.V. infusion 500 mg in 50 mL	1199.32	18.94%	972.17	1199.32	18.94%	Does not meet 30 month clock	10
rosuvastatin*	Oral	Tablet 10 mg (as calcium)	5.14	38.52%	3.16	5.14	38.52%	GWAPD	30
tenofovir	Oral	Tablet containing tenofovir disoproxil fumarate 300 mg	339.37	11.93%	298.88	339.37	11.93%	Does not meet 30 month clock	10
tenofovir	Oral	Tablet containing tenofovir disoproxil maleate 300 mg	339.37	11.93%	298.88	339.37	11.93%	Does not meet 30 month clock	10
tenofovir	Oral	Tablet containing tenofovir disoproxil phosphate 291 mg	339.37	11.93%	298.88	339.37	11.93%	Does not meet 30 month clock	10
teriflunomide	Oral	Tablet 14 mg	628.85	18.71%	511.19	628.85	18.71%	Does not meet 30 month clock	10
tobramycin	Injection	Injection 80 mg (as sulfate) in 2 mL (without preservative)	23.00	11.87%	20.27	23.00	11.87%	GWAPD	10
tobramycin	Injection	Injection 80 mg in 2 mL	21.00	11.86%	18.51	21.00	11.86%	GWAPD	10
trastuzumab	Injection	Powder for I.V. infusion 150 mg	533.22	11.81%	470.25	533.22	11.81%	Does not meet 30 month clock	10
trastuzumab	Injection	Powder for I.V. infusion 420 mg	1493.02	11.81%	1316.69	1493.02	11.81%	Does not meet 30 month clock	10
trastuzumab	Injection	Powder for I.V. infusion 60 mg	213.29	11.81%	188.10	213.29	11.81%	Does not meet 30 month clock	10
trastuzumab	Injection	Solution for subcutaneous injection containing trastuzumab 600 mg in 5 mL	1667.10	11.81%	1470.22	1667.10	11.81%	Does not meet 30 month clock	10
zoledronic acid	Injection	Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL	132.37	38.31%	72.79	118.00	38.31%	GWAPD	30
zoledronic acid	Injection	Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL	132.37	38.31%	72.79	118.00	38.31%	GWAPD	30
zoledronic acid	Injection	Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL	177.21	38.31%	97.47	157.98	38.30%	GWAPD	30

Price Disclosure Reductions for 2020 October Cycle

Flow-on Reductions for F2 Combination Items

Legal Determination & Next Steps

2020 October Cycle Outcomes Summary

Department of Health and Aged Care

Pharmaceutical Benefits Scheme

PBS Information

Browse the PBS

For Health Professionals

For Industry